Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice

Endocrinology

Volumn 141, Issue 10, 2000, Pages 3703-3709

  Baggio, Laurie ^a   Kieffer, Timothy J ^b   Drucker, Daniel J ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN[9-39]; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HORMONE; HORMONE ANTAGONIST; HORMONE RECEPTOR; INSULIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONE ACTION; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 0033744922     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.10.7720     Document Type: Article

References (43)

1. Entero-insular axis
2. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide
3. The glucagon-like peptides
4. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
5. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
6. Glucagon-like peptide-l(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute postprandial and 24-h secretion patterns
7. The glucagon-like peptides
8. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
9. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells
10. Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription
11. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats
12. Effect of GIP and GLP-1 antagonists on insulin release in the rat
13. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
14. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene
15. Neuroendocrine function in mice with complete disruption of GLP-1 receptor signaling
16. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice
17. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor agonist
18. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
19. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
20. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells
21. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: Ligand binding and intracellular signalling properties
22. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor
23. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases
24. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide
25. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
26. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (non-insulin dependent) diabetic patients
27. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
28. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: A physiological role of glucagon-like peptide I
29. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
30. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
31. Glucose homeostasis in mice with disruption of GLP-1 receptor signaling
32. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with GLP-1 receptor null phenotype
33. Effects of aging and a high fat diet on body weight and glucose control in GLP-1R-/- mice
34. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39
35. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons
36. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
37. Exendin-(9-39) as an inverse agonist of the murine GLP-1 receptor. Implications for basal intracellular cAMP levels and β-cell glucose competence
38. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat
39. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN1046-38 cells
40. Mouse pancreatic beta cells exhibit preserved glucose competence after disruption of the glucagon-like peptide 1 receptor gene
41. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
42. Is glucagon-like peptide 1 an incretin hormone?